论文部分内容阅读
目的 观察福辛普利对充血性心力衰竭 (Congestiveheartfailure ,CHF)患者血浆内皮素 (Endothelin ,ET)水平及心功能变化的影响 ,并探讨其相关机制。方法 采用放射免疫法检测福辛普利组及常规治疗对照组患者治疗前和治疗 12周后血浆ET水平 ,同时间点采用超声心动图检测左室射血分数 (Leftventricularejectionfraction ,LVEF)和二尖瓣血流最大流速E峰和A峰比值 (E/A) ,并以 38例健康体检者作为正常对照组。结果 CHF患者ET水平显著高于对照组 ,福辛普利治疗 12周后 ,CHF患者的ET水平显著降低 ,LVEF、E/A值显著提高。结论 CHF患者ET水平增高可作为判断CHF病情的指标之一 ;福辛普利可降低CHF患者的ET水平 ,改善CHF患者的心脏功能。
Objective To observe the effect of fosinopril on plasma endothelin (ET) and cardiac function in patients with congestive heart failure (CHF) and to explore its mechanism. Methods Plasma ET levels were measured before and 12 weeks after treatment in patients receiving fosinopril and conventional therapy by radioimmunoassay. Meanwhile, left ventricular ejection fraction (LVEF) and mitral valve The maximum flow velocity E peak and A peak ratio (E / A), and 38 healthy subjects as a normal control group. Results The ET level of CHF patients was significantly higher than that of the control group. After fosinopril treatment for 12 weeks, the ET levels of CHF patients were significantly decreased, and the LVEF and E / A values were significantly increased. Conclusion The increased ET level in CHF patients may be one of the indexes to judge the severity of CHF. Fosinopril may decrease the ET level in CHF patients and improve the cardiac function in CHF patients.